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Abstract
Cancer-related cognitive impairment (CRCI) is a concerning problem for many cancer survivors. Evaluating patients for CRCI
has been a challenge, in part because of a lack of standardized practices. Self-report instruments are often used to assess
CRCI, but there are no validated cutpoints. We present the results of receiver operating characteristic curve analysis identify-
ing cutpoints of the Functional Assessment of Cancer Therapy—Cognition perceived cognitive impairment (PCI) in female
breast cancer survivors for identifying CRCI cases. We defined presence of CRCI based on elevated complaints on the Patient’s
Assessment of Own Functioning Inventory compared with healthy control scores. Our results indicate that scores less than
54 in PCI scores using 18 items and scores less than 60 in PCI scores using 20 items exhibited good ability to discriminate CRCI
cases from noncases (area under the receiver operating characteristic curve was 0.84 [95% CI ¼ 0.73 to 0.94]). These prelimi-
nary results represent an important contribution toward standardizing practices across CRCI studies.
Cognitive problems after cancer and its treatment, often re-
ferred to as cancer-related cognitive impairment (CRCI), are a
concerning adverse effect for many survivors. Evaluating CRCI
in research and clinical settings is challenging without stan-
dardized methods for classification. Self-report measures of
cognitive dysfunction (1) are often preferred for assessing CRCI,
but there are no established cutpoints for some of the most
commonly used instruments. Common measures and cutpoints
for classifications are important for standardizing definitions of
CRCI. Further, it is difficult to compare study samples and eval-
uate potential interventions without definitions of “caseness.”
The Functional Assessment of Cancer Therapy—Cognition
(FACT-Cog) (2,3) was developed specifically to assess cognitive
difficulties in cancer survivors, and it is regularly employed in
observational and treatment studies (4,5). For version 3 of the
FACT-Cog, the scale developers recommend using one of the
four subscores, the perceived cognitive impairment (PCI) score,
as the preferred outcome (6), and it is the one most often cited
in the literature. Surprisingly, no cutpoints have yet been estab-
lished for the PCI score. To address this gap, we examined the
receiver operating characteristic (ROC) curves for the PCI score
against a validated CRCI classification measure, and then exam-
ined the performance of emergent cutpoints.
The Mind Body Study was a prospective longitudinal study
examining the effects of breast cancer treatments on cognitive
functioning from the end of primary treatment through 6 years.
The study has been previously described in detail, and it in-
volved intensive cognitive and psychosocial assessments (7–9).
The FACT-Cog version 3 was added at the final timepoint of this
study (approximately 3–6 years after participants completed pri-
mary cancer treatment), and we examined data only from this
time point in a cross-sectional manner for this report.
Participants were recruited through clinical oncology practi-
ces and rapid case ascertainment of stage-eligible patients from
collaborating physicians and hospitals identified through the
Los Angeles Surveillance, Epidemiology, and End Results
Program registry. Participants were aged 21–65 years, had a re-
cent early-stage breast cancer diagnosis, and completed pri-
mary treatment within the last 3 months (8). Women with
active psychotic or major depressive disorders, or any history of
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treatments or conditions with known effects on cognition or in-
flammation, were excluded. The UCLA institutional review
board approved the study, and all participants provided written
informed consent.
All participants completed the FACT-Cog version 3 at the
last longitudinal follow-up assessment; this version was after
study initiation and added to this time point because it was a
standard in studies of this population (2,3). Standard scoring
yields four domain scores, and for this report we focus only on
the PCI, which includes 20 items total. Historically, only 18
were scored to get the PCI (PCI-18; range 0-72), but there is now
more evidence to support the validity of including all 20 items
in the score (PCI-20; range 0-80) (10); this report examines both
PCI-18 and PCI-20 scores.
Participants also completed the Patient’s Assessment of
Own Functioning Inventory (PAOFI) (11), commonly used to
capture self-assessed difficulties in various populations across
several domains of cognitive function. The PAOFI total is calcu-
lated based on the number of items rated as high severity,
ranging from 0–33, in which higher is worse functioning.
Comparison PAOFI data were available from healthy control
women without breast cancer enrolled in a study at the
University of California, San Diego (UCSD) (12) (n¼ 63; mean
age 51.96 [6 9.35 years]; 63%  college education; 79% white),
and used in earlier Mind Body Study reports to classify cogni-
tive impairment in the breast cancer patients (8). Cognitive im-
pairment on the PAOFI total was established as greater than
2SDS above the mean of the healthy control sample (ie, > 6 on
the PAOFI total in healthy women) (8).
Sixty percent of the breast cancer survivor sample was ran-
domly selected for the training dataset, and 40% for the valida-
tion dataset using a random number generator in SPSS. We
plotted two ROC curves using the training dataset for each PCI
score and manually identified the cutpoint yielding highest sen-
sitivity and specificity estimates. We then calculated estimates
of sensitivity specificity, positive predictive validity (PPV), and
negative predictive validity (NPV) in the validation dataset.
Analyses were conducted using SPSS (IBM SPSS Statistics for
Windows, V.24.0. Armonk, NY: IBM Corp).
A total of 133 breast cancer survivors were evaluated; see
Table 1 for sample demographics. There were 80 survivors in
the training dataset and 53 in the validation data set. The train-
ing dataset consisted of 17 impaired and 63 not impaired partic-
ipants; the validation dataset consisted of 14 and 39,
respectively.
The area under the ROC curve was 0.84 (95% CI ¼ 0.73 to 0.94)
for both PCI-18 and PCI-20. Examining the coordinates of the
ROC curves for each measure, the following cutpoint scores
were identified in the training set: PCI-18 less than 54, 76% sen-
sitivity, and 82% specificity; PCI-20 less than 60, 76% sensitivity,
84% specificity. These cutpoints exhibited good classification
performance in the validation dataset; see Table 2.
This report is the first to describe cutpoints on the FACT-Cog
PCI to classify CRCI. In addition to the commonly used 18-item
PCI, we also examined the full 20-item PCI, which is currently
being validated and used in the research community (10). Both
PCI-18 and PCI-20 showed good discriminative ability to classify
CRCI.
Table 1. Demographics of breast cancer survivor sample
Whole sample Training set* Validation set*
(n¼ 133) (n¼ 80) (n¼ 53)
Age, mean (SD), y 56.61 (7.82) 56.35 (8.7) 57 (6.32)
Education ( college), No. (%) 68 (51) 62 (78) 45 (85)
Race (% white), No. (%) 106 (80) 62 (78) 44 (83)
Years since Dx, mean (SD) 4.31 (0.64) 4.23 (0.63) 4.26 (0.66)
Chemotherapy Tx No. (%) 73 (55) 49 (61) 24 (45)
Radiation Tx No. (%) 100 (75) 59 (74) 41 (77)
Stage at diagnosis No. (%)
0 19 (14) 11 (14) 8 (15)
I 58 (44) 30 (38) 28 (53)
II 44 (33) 30 (38) 14 (26)
III 12 (9) 9 (11) 3 (6)
Estimated verbal IQ (WTAR), mean (SD) 114.74 (8.78) 115.60 (8.67) 113.43 (8.85)
*No differences between groups on any variable based on t test or X2, p greater than .05. Dx = diagnosis; Tx = treatment; WTAR = Wechsler Test of Adult Reading.
Table 2. Classification performance of FACT-Cog PCI in the validation dataset*
Classification
Sensitivity Specificity PPV NPV
Impaired Not impaired (95% CI)† (95% CI) (95% CI) (95% CI)
PCI - 18 (< 54) Impaired 11 3 79 92 79 92
Not impaired 3 36 (49 to 95) (79 to 98) (49 to 95) (79 to 98)
PCI - 20 (< 60) Impaired 11 3 79 92 79 92
Not impaired 3 36 (49 to 95) (79 to 98) (49 to 95) (79 to 98)
*FCIs are exact binomial confidence intervals. FACT-Cog ¼ Functional Assessment of Cancer Therapy—Cognition PCI ¼ perceived cognitive impairment; PPV ¼ positive
predictive value; NPV ¼ negative predictive value.
†CIs are exact binomial confidence intervals.
2 of 3 | JNCI Cancer Spectrum, 2020, Vol. 4, No. 1
The field of CRCI is presently lacking in standardized classifi-
cation methods using targeted subjective instruments, and
these findings offer a valuable starting point. Cutpoints can
help standardize methods and CRCI definitions across research
studies to improve congruity and accelerate progress. Cutpoints
may also be useful for identifying patients in need of services,
but this would require further study.
This study has limitations in that it is a relatively small and
exploratory extension of a larger study of breast cancer survi-
vors—not specifically designed to test whether these cutpoints
have relevance for a variety of important outcomes (eg, func-
tioning). In addition, participants in our sample were several
years out from completing cancer treatments, which could call
into question the validity of these cutpoints in patients and sur-
vivors more proximal to undergoing treatment. Future research
will be important to validate the relevance of these cutpoints in
other varied cancer populations.
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